Share of the population living with HIV receiving antiretroviral therapy in Montenegro

Montenegro: Share of the population living with HIV receiving antiretroviral therapy was 61.0% in 2024. ◆ Volatile

Latest (2024)
61.0%
Change on year
up 4.7%
World rank
108th
of 149 countries
All-time high
61.0%
in 2024
All-time low
0.0%
in 1990
Years of data
35
1990–2024

Share of the population living with HIV receiving antiretroviral therapy in Montenegro, 1990–2024

02040601990200720241990: 0 %1991: 0 %1992: 0 %1993: 0 %1994: 0 %1995: 0 %1996: 0 %1997: 0 %1998: 0 %1999: 4.2 %2000: 7.6 %2001: 10.6 %2002: 11.3 %2003: 12.8 %2004: 15.2 %2005: 20.1 %2006: 20.6 %2007: 22.5 %2008: 23.7 %2009: 25.2 %2010: 28.2 %2011: 27.4 %2012: 28.2 %2013: 30.8 %2014: 33.6 %2015: 34.4 %2016: 40.1 %2017: 44.9 %2018: 48.8 %2019: 51.6 %2020: 52.3 %2021: 51.7 %2022: 53.1 %2023: 58.2 %2024: 61 %

Source: Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data. Measured in %.

Analysis

In 2024, share of the population living with hiv receiving antiretroviral therapy in Montenegro stood at 61.0%. That is the highest value across all 35 years on record.

That represents a change of up 4.7% on the previous year and up 81.3% over ten years.

Over the whole period, share of the population living with hiv receiving antiretroviral therapy in Montenegro peaked at 61.0% in 2024 and was at its lowest, 0.0%, in 1990.

Montenegro ranks 108th of 149 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Share of the population living with HIV receiving antiretroviral therapy in Montenegro, year by year

Annual values for Share of the population living with HIV receiving antiretroviral therapy in Montenegro, 1990 to 2024.
Year % Change
1990 0.0% —
1991 0.0% —
1992 0.0% —
1993 0.0% —
1994 0.0% —
1995 0.0% —
1996 0.0% —
1997 0.0% —
1998 0.0% —
1999 4.2% —
2000 7.6% +83.2%
2001 10.6% +39.4%
2002 11.3% +6.3%
2003 12.8% +13.1%
2004 15.2% +19.0%
2005 20.1% +32.4%
2006 20.6% +2.5%
2007 22.5% +9.1%
2008 23.7% +5.5%
2009 25.2% +6.1%
2010 28.2% +12.1%
2011 27.4% -2.9%
2012 28.2% +3.0%
2013 30.8% +9.0%
2014 33.6% +9.3%
2015 34.4% +2.3%
2016 40.1% +16.5%
2017 44.9% +12.1%
2018 48.8% +8.7%
2019 51.6% +5.6%
2020 52.3% +1.4%
2021 51.7% -1.1%
2022 53.1% +2.6%
2023 58.2% +9.7%
2024 61.0% +4.7%

Montenegro compared with similar countries

  • Montenegro's 61.0% is below the median for upper middle income countries, which is 65.5%, 93% of the median. (43 countries reporting)
  • Montenegro's 61.0% is below the median for Europe & Central Asia, which is 82.9%, 74% of the median. (34 countries reporting)

Biggest year-on-year movements

Years where Share of the population living with HIV receiving antiretroviral therapy in Montenegro changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2000 +83.2% 4.2% 7.6%

Averages by decade

DecadeAverage LowestHighest Years
1990s 0.4% 0.0% 4.2% 10
2000s 17.0% 7.6% 25.2% 10
2010s 36.8% 27.4% 51.6% 10
2020s 55.3% 51.7% 61.0% 5

Countries ranked near Montenegro

  1. 105 Costa Rica 61.6% compare
  2. 106 Albania 61.3% compare
  3. 107 Saint Kitts and Nevis 61.1% compare
  4. 109 East Timor 60.8% compare
  5. 110 Malaysia 60.4% compare
  6. 111 Barbados 60.4% compare

See the full ranking of 149 places →

More reference data data for Montenegro

All data for Montenegro →

Frequently asked questions

What is share of the population living with hiv receiving antiretroviral therapy in Montenegro?
Share of the population living with hiv receiving antiretroviral therapy in Montenegro was 61.0% in 2024, according to Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data.
What is the highest share of the population living with hiv receiving antiretroviral therapy recorded in Montenegro?
The highest recorded value was 61.0% in 2024.
What is the lowest share of the population living with hiv receiving antiretroviral therapy recorded in Montenegro?
The lowest recorded value was 0.0% in 1990.
How does Montenegro rank for share of the population living with hiv receiving antiretroviral therapy?
Montenegro ranks 108th out of 149 countries with data for 2024.
Is share of the population living with hiv receiving antiretroviral therapy rising or falling in Montenegro?
Over the last ten years it is up 81.3%. The long-run trend across the full record is volatile.
Where does this Montenegro data come from?
The figures come from Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as part of Share of the population living with HIV receiving antiretroviral therapy. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (Our World in Data).

Share, cite or embed this page

Cite this page

Share of the population living with HIV receiving antiretroviral therapy in Montenegro. Statizoid, drawing on Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data. Retrieved 29 September 2026, from https://reference.statizoid.com/stat/gap-to-reaching-the-target-of-art/montenegro/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (Our World in Data); please keep the attribution.

<a href="https://reference.statizoid.com/stat/gap-to-reaching-the-target-of-art/montenegro/">Share of the population living with HIV receiving antiretroviral therapy in Montenegro</a> — Statizoid

About this data

Indicator
Share of the population living with HIV receiving antiretroviral therapy
Unit
%
Source
Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
149 places, 5,062 data points, 1990–2024
Last refreshed

Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.